ELOX Key Statistics, Chart & Performance
The current stock price of ELOX is 3.82 USD. In the past month the price decreased by -35.03%. In the past year, price decreased by -40.31%.
ELOX Technical Analysis
ELOX Financial Highlights
Over the last trailing twelve months ELOX reported a non-GAAP Earnings per Share(EPS) of -11.36. The EPS increased by 43.2% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -407.11% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ELOX Forecast & Estimates
7 analysts have analysed ELOX and the average price target is 61.2 USD. This implies a price increase of 1502.09% is expected in the next year compared to the current price of 3.82.
ELOX Ownership
About ELOX
Company Profile
Eloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid-modulating drug candidates. The company is headquartered in Watertown, Massachusetts and currently employs 18 full-time employees. The company went IPO on 2012-11-23. The firm is engaged in the science of ribosome modulation, leveraging both its TURBO- ZM chemistry technology platform and its library of aminoglycosides to develop oral small-molecule ribosome modulating agents (RMAs) and eukaryotic ribosome selective glycosides (ERSGs) for the treatment of rare and ultra-rare genetic diseases. Its lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. The firm is also advancing ZKN-013 as an oral agent for the treatment of recessive dystrophic (RDEB)/ junctional epidermolysis bullosa (JEB) and familial adenomatous polyposis (FAP) patients with nonsense mutations. The firm also has preclinical programs focused on select rare diseases, including inherited diseases, cancer caused by nonsense mutations, kidney diseases, as well as rare ocular genetic disorders.
Company Info
ELOXX PHARMACEUTICALS INC
480 Arsenal Way, Suite 130
Watertown MASSACHUSETTS 02451 US
CEO: Gregory C. Williams
Employees: 18
Phone: 17815775300.0
ELOXX PHARMACEUTICALS INC / ELOX FAQ
What does ELOXX PHARMACEUTICALS INC do?
Eloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid-modulating drug candidates. The company is headquartered in Watertown, Massachusetts and currently employs 18 full-time employees. The company went IPO on 2012-11-23. The firm is engaged in the science of ribosome modulation, leveraging both its TURBO- ZM chemistry technology platform and its library of aminoglycosides to develop oral small-molecule ribosome modulating agents (RMAs) and eukaryotic ribosome selective glycosides (ERSGs) for the treatment of rare and ultra-rare genetic diseases. Its lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. The firm is also advancing ZKN-013 as an oral agent for the treatment of recessive dystrophic (RDEB)/ junctional epidermolysis bullosa (JEB) and familial adenomatous polyposis (FAP) patients with nonsense mutations. The firm also has preclinical programs focused on select rare diseases, including inherited diseases, cancer caused by nonsense mutations, kidney diseases, as well as rare ocular genetic disorders.
Can you provide the latest stock price for ELOXX PHARMACEUTICALS INC?
The current stock price of ELOX is 3.82 USD. The price decreased by -5.68% in the last trading session.
What is the dividend status of ELOXX PHARMACEUTICALS INC?
ELOX does not pay a dividend.
How is the ChartMill rating for ELOXX PHARMACEUTICALS INC?
ELOX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
On which exchange is ELOX stock listed?
ELOX stock is listed on the Nasdaq exchange.
What is the employee count for ELOX stock?
ELOXX PHARMACEUTICALS INC (ELOX) currently has 18 employees.
What is the market capitalization of ELOX stock?
ELOXX PHARMACEUTICALS INC (ELOX) has a market capitalization of 10.70M USD. This makes ELOX a Nano Cap stock.